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The remarkable tenacity of sulfadoxine-pyrimethamine
Plasmodium falciparum infection during pregnancy 
causes low birthweight in the newborn, which is a risk 
factor for infant mortality.1 Intermittent preventive 
treatment in pregnancy (IPTp) with sulfadoxine-
pyrimethamine was introduced with the primary aim of 
ameliorating the effect of malaria on birthweight. At the 
time of its introduction 15–20 years ago, many countries 
were still using sulfadoxine-pyrimethamine as the 
first-line treatment for malaria. Concerns immediately 
arose about the spread of sulfadoxine-pyrimethamine-
resistant malaria and the effect of resistance on the 
effectiveness of the drug combination for both the 
treatment and prevention of malaria. Over the past 
decade, all countries in sub-Saharan Africa have changed 
their first-line treatment of malaria to an artemisinin-
based combination therapy, raising the possibility that 
sulfadoxine-pyrimethamine resistance might begin to 
decrease in prevalence. However, in contrast to the re-
emergence of chloroquine-susceptible malaria after the 
removal of drug pressure,2 sulfadoxine-pyrimethamine 
resistance seems to be fixed in the parasite population 
in Africa, despite its withdrawal from use as the first-
line treatment for uncomplicated disease.3 This fixation 
might be due to the use of sulfadoxine-pyrimethamine 
for IPTp, or the frequent use of another antifolate 
drug combination, co-trimoxazole (trimethoprim-
sulfamethoxazole), for the treatment of bacterial 
infection and for prophylaxis among people living with 
HIV. Regardless of the mechanism of its persistence, 
sulfadoxine-pyrimethamine resistance seems to be here 
to stay.
In The Lancet Infectious Diseases, Anna Maria van 
Eijk and colleagues4 report results of a meta-analysis 
of aggregated-data from 57 studies (involving 
59 457 births) and of individual-patient data from 
13 surveys (42 394 births), assessing the effect of 
sulfadoxine-pyrimethamine resistance on sulfadoxine-
pyrimethamine IPTp effectiveness. van Eijk and 
colleagues collected data on molecular markers of 
sulfadoxine-pyrimethamine resistance from published 
reports, individual authors, and population prevalence 
maps compiled by the Worldwide Antimalarial Resistance 
Network (WWARN). Data on transmission intensity were 
collected from the Malaria Atlas Project. The investigators 
categorised study areas as having low, moderate, or high 
resistance by exploring various thresholds of prevalence 
of three mutations in the P falciparum dhps gene: 
Lys540Glu, Ala437Gly, and Ala581Gly. The distribution 
of sulfadoxine-pyrimethamine-resistant genotypes 
differed: in east and southern Africa, the high prevalence 
of dhps Lys540Glu defined high-level resistance to 
sulfadoxine-pyrimethamine, but was rarely identified in 
central and west Africa, where dhps Ala437Gly prevalence 
distinguished low from moderate levels of resistance. 
Pooled estimates from the aggregated-data meta-
analysis suggested that protection from low birthweight 
decreases with increasing prevalence of dhps Lys540Glu 
(Ptrend=0·0060), but is unaffected by the prevalence of 
dhps Ala437Gly mutations (Ptrend=0·35). The individual-
participant analysis of survey data, however, shows the 
resilience of sulfadoxine-pyrimethamine IPTp, with a 
protective effect even in areas with a dhps Lys540Glu 
prevalence of more than 90% and Ala581Gly prevalence 
of less than 10% (relative risk reduction [RRR] 10% 
[95% CI 7–12%]). This protection waned in areas with 
both a high prevalence of dhps Lys540Glu and a dhps 
Ala581Gly prevalence of 10% or higher (RRR 0·5% 
[–16 to 14]), but this most extreme resistant genotype 
was only found in a small number of locations in 
east Africa.
The need for such a large meta-analysis to link 
sulfadoxine-pyrimethamine resistance to its protective 
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efficacy against low birthweight has been clear for many 
years. Although the failure of sulfadoxine-pyrimethamine 
to treat and prevent malaria infection during pregnancy 
has been documented by numerous studies,5 any effect 
of the decreased antimalarial efficacy of sulfadoxine-
pyrimethamine with respect to birthweight has been 
difficult to detect. Given the challenges of conducting 
clinical trials in pregnant women6 and the variable 
attributable fraction of malaria to low birthweight,7 
this report shows the catalytic impact that data-sharing 
platforms, such as those established by WWARN and the 
Malaria Atlas Project, can have to translate research data 
into evidence to inform public health.
The results of this study have important implications 
for the types of data that policy makers require to 
predict the efficacy of sulfadoxine-pyrimethamine IPTp. 
In low-resource settings, it might be most beneficial to 
limit molecular testing to dhps Ala581Gly in east and 
southern Africa and to include dhps Ala437Gly in west 
and central Africa. However, to accurately model the 
future risk of widespread sulfadoxine-pyrimethamine 
IPTp failure, we must better understand how resistance 
emerges and the factors that drive parasite gene flow 
across geo graphic regions. Why are quintuple-mutant 
sulfadoxine-pyrimethamine-resistant parasites so 
rare in west and central Africa? Why is the highly 
resistant dhps Ala581Gly present in only a few settings 
and only in the context of the quintuple mutant? 
What conditions favour or discourage the emergence 
and spread of sulfadoxine-pyrimethamine-resistant 
parasites? Previous experience does not provide clear 
answers to these questions. Although chloroquine-
resistant malaria emerged a few times in distinct 
geographic locations, the genomic analysis of the 
spread of artemisinin-resistant malaria indicates 
both independent emergence and also geographic 
spread.8 The combination of the types of integrated 
international database collaborations described by 
van Eijk and colleagues, along with new methods in 
genomics and modelling, will allow us to not only 
track the failure of drugs, but also to be proactive in 
developing interventions to limit the spread and impact 
of antimalarial drug resistance. 
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A new social sciences network for infectious threats
The Ebola epidemic in the Democratic Republic of the 
Congo (DRC) continues to escalate, new outbreaks of 
Lassa fever, yellow fever, measles, and other infectious 
diseases erupt around the world, and antimicrobial 
resistance intensifies from unmanaged use of these 
drugs. These infectious threats are intertwined 
with political and economic instability, changing 
ecological conditions, livestock management and 
food production practices, and local communities 
and their marginalised populations.1,2 The challenge 
in addressing these health security threats surpasses 
conventional response strategies. National govern- 
ments and international agencies struggle to 
understand popular reactions to infectious disease 
emergence and outbreaks and to control deadly 
diseases.3
